Products for Research Use Only
RegisterLogin

Brincidofovir

CAT: 0804-HY-14532-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14532-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir , is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo[1][2][3][4].
CAS Number
444805-28-1
Product Name Alternative
CMX001; HDP-CDV
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
CMV; HSV; Orthopoxvirus
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/CMX001.html
Purity
99.46
Solubility
0.1 M NaOH : 50 mg/mL (ultrasonic) |DMSO : 1 mg/mL (adjust pH to 8 with NaOH; heat to 50°C)
Smiles
NC1=NC(N(C[C@@H](CO)OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)C=C1)=O
Molecular Formula
C27H52N3O7P
Molecular Weight
561.69
Precautions
H302, H315, H319
References & Citations
[1]Hiwarkar P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129 (14) :2033-2037.|[2]Detweiler CJ, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018;40 (6) :e364-e368.|[3]Zaitseva M, McCullough KT, Cruz S, et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol. 2015;89 (6) :3295-3307.|[4]Scott A Foster , et al. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses. 2017 Oct 30;9 (11) :320.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
BUP09087-01Brincidofovir
CS-O-60364Brincidofovir-d5
MBS384527-01Brincidofovir (CMX001)
443431-01Brincidofovir (CMX 001)
A13326-50Brincidofovir (CMX001) 50mg
A13326-1Brincidofovir (CMX001) 1mg
A13326-100Brincidofovir (CMX001) 100mg
A13326-25Brincidofovir (CMX001) 25mg
A13326-200Brincidofovir (CMX001) 200mg
A13326-10Brincidofovir (CMX001) 10mg

Popular Products